🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

RecruitingPhase 2, Phase 3Ages 18 Years - anyAllLinnaeus Therapeutics, Inc.
NCT06624644 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will compare LNS8801 taken alone or LNS8801 taken together with another drug called pembrolizumab to other therapies as decided by the treating doctor. 135 patients will be randomly (like flipping a coin) placed in 3 treatment groups. In the first group (LNS8801 only) - Patients will take 125mg tablet of LNS8801 by mouth once per day every day for up to 2 years. In the second group (LNS8801 + pembrolizumab) - Patients will take 125mg tablet of LNS8801 by mouth once per day plus 200 mg of pembrolizumab by IV infusion once every 3 weeks for up to 2 years. In the third group, called Physician's Choice

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Confirmed unresectable and/or metastatic cutaneous melanoma. * 2 copies of the fully functional form of GPER protein-coding sequence. * Eligible for and willing to receive 1 or more of the physician's choice (PC) therapies. * Able to swallow tablets. * Progressed on treatment with an anti-PD-1 monoclonal antibody (mAb) administered either as monotherapy or in combination with other therapies. * Received an anti-CTLA-4 and/or BRAF containing regimen or is not eligible for or has declined anti-CTLA-4 and/or BRAF therapy prior to and for this study. * Measurable disease. * Eastern Cooperative Oncology Group Performance Status of 0 to 1. Exclusion Criteria: * Blue nevus subtype, mucosal, acral lentiginous, or uveal/ocular/choroidal Melanoma. * Previous anti-cancer or investigational drug/device treatment within 4 weeks of the first dose of study drug. * Radiotherapy within 2 weeks of starting study drug. * Allogeneic tissue/solid organ transplant. * Unstable autoimmune or immunodeficiency disease. * Other concurrent health issues that would make participation or completion of the study difficult. * Prior reaction to anti PD-1 therapy that would make treatment with pembrolizumab unadvisable. * Other protocol-defined inclusion/exclusion criteria may apply.
💊

What it tests

  • LNS8801
  • Pembrolizumab
  • Chemotherapy (dacarbazine or temozolomide)
  • Immunotherapy (Pembrolizumab)
  • Immunotherapy (nivolumab and relatlimab)
📍

Where

9 sites
USC Newport Beach
Newport Beach, United States
UCSF
San Francisco, United States
Stanford
Stanford, United States
University of Colorado Anschutz
Aurora, United States
University of Colorado
Denver, United States
Moffitt Cancer Center
Tampa, United States
Dana Farber
Boston, United States
University of New Mexico
Albuquerque, United States

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy